Marinomed Biotech AG develops first medicinal product for the treatment of autoimmune gastritis

By: Marinomed Biotech AG
 
VIENNA - Oct. 8, 2020 - PRLog -- ·       Cooperation with the Medical University of Vienna to research new treatments for autoimmune gastritis

·       Technology platform Marinosolv® as basis for anti-inflammatory formulations

·       Marinomed obtains patent for the development of autoimmune gastritis treatment and its commercial marketing

·       Broadening of the Marinosolv® technology platform

Marinomed Biotech AG, a Vienna-based biopharmaceutical company, develops groundbreaking treatment for autoimmune gastritis together with the Medical University of Vienna. Aided by the Marinosolv® technology platform, for the first time, the focus will be on an anti-inflammatory treatment rather than treating only the deficiency symptoms. "The goal of Marinomed is to solve the unsolvable using Marinosolv®.

We are delighted to work together with experts in their field, Priv.-Doz. Stefanie Dabsch and ao. Univ.-Prof. Christoph Gasche. So far there is no anti-inflammatory treatment for autoimmune gastritis and together we will change that. Priv.-Doz. Stefanie Dabsch and ao. Univ.-Prof. Christoph Gasche as well as their team from the Medical University of Vienna bring extensive knowledge regarding the disease to the table, while we have the necessary galenic know-how. For patients, this would mean a milestone in their treatment", says Marinomed-CEO Andreas Grassauer.

Together with a team of renowned researchers based at the Medical University of Vienna, Marinomed Biotech AG is developing a medicinal product, that focuses on the anti-inflammatory treatment of autoimmune gastritis. Basis is the technology platform Marinosolv® which was developed and patented by Marinomed and has a good track record in mucosal applications. Anti-inflammatory drugs will be applied locally in the stomach in order to act predominantly in affected areas. The local application will severely reduce systemic effects and potential side effects. The inflammation, triggered by autoantibodies, will be stopped and the gastric mucosa can recover.

In doing so, Marinomed Biotech AG is broadening the Marinosolv® technology platform by an application in the gastrointestinal tract. The company will take over the commercialization of the novel drug product. For this, the University transferred the respective patent to Marinomed Biotech AG

For further enquiries please contact:

Dr. Eva Prieschl-Grassauer

Chief Scientific Officer, Marinomed

Hovengasse 25, 2100 Korneuburg, Österreich

T +43 2262 90300

E-Mail: eva.prieschl@marinomed.com

http://www.marinomed.com

Contact
PR&D
***@prd.at
End
Email:***@prd.at Email Verified
Tags:Marinomed
Industry:Health
Location:Vienna - Vienna - Austria
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
PR&D - Public Releations for Research & Education PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share